Document:

License and Settlement Agreement, dated as of August 4, 2011

 Exhibit 10.2 
 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 LICENSE AND SETTLEMENT AGREEMENT

 THIS LICENSE AND SETTLEMENT AGREEMENT (this “Agreement”) dated as of August 4, 2011 (the
“Effective Date”) is entered into between Medicis Pharmaceutical Corporation, a Delaware corporation with offices located at 7720 North Dobson Road, Scottsdale, Arizona 85256, U.S.A. (collectively with its Affiliates,
“Medicis”), and Nycomed US Inc., a New York corporation with offices located at 60 Baylis Road, Melville, New York 11747 (collectively with its Affiliates, “Nycomed”). Medicis and Nycomed are each sometimes referred
to herein individually as a “party” and are referred to collectively as the “parties.” 
 WHEREAS, Medicis
has asserted various claims and causes of action against Nycomed in actions captioned Medicis Pharmaceutical Corporation v. Nycomed US Inc. and Nycomed GmbH, Civil Action No. 10-CV-4140 (S.D.N.Y.) (DLC), Medicis Pharmaceutical
Corporation v. Nycomed US Inc. and Nycomed GmbH, Civil Action No. 11-CV-2630 (S.D.N.Y.) (DLC), and Medicis Pharmaceutical Corporation v. Nycomed US Inc., Civil Action No. 11-CV-4551 (S.D.N.Y.) (DLC) (the
“Litigations”), which are pending in the United States District Court for the Southern District of New York (the “Court”). 
 WHEREAS, Medicis and Nycomed seek to resolve the Litigations without further litigation; 
 WHEREAS, Medicis is the owner of the Patent Rights (as defined below); and 

WHEREAS, Nycomed desires to receive a license under the Patent Rights and Medicis desires to grant to Nycomed a license under the Patent
Rights, all on the terms and conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the
mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

 

	 	1.	DEFINITIONS. 

 1.1
“Affiliate” means, with respect to any entity, any other entity that directly or indirectly controls, is controlled by, or is under common control with, such entity. An entity shall be regarded as in control of another entity if it
owns, or directly or indirectly controls, at least fifty percent (50%) of the voting stock or other ownership interest of the other entity, or if it directly or indirectly possesses the power to direct or cause the direction of the management
and policies of the other entity by any means whatsoever. 
 1.2 “ANDA” means an Abbreviated New Drug
Application and any supplements thereto. 
 1.3 “Authorized Generic” means ***. 

 1.4 “Confidential Information” means all non-public materials, information
and data concerning the disclosing party and its operations that is disclosed by the disclosing party to the receiving party pursuant to this Agreement, orally or in written, electronic or tangible form, or otherwise obtained by the receiving party
through observation or examination of the disclosing party’s operations. Confidential Information includes, but is not limited to, information about the disclosing party’s financial condition and projections; business, marketing or
strategic plans; sales information, customer lists; price lists; databases; trade secrets; product prototypes and designs; techniques, formulae, algorithms and other non-public process information. Notwithstanding the foregoing, Confidential
Information of a party shall not include that portion of such materials, information and data that, and only to the extent, the receiving party can establish by written documentation: (a) is known to the receiving party as evidenced by its
written records before receipt thereof from the disclosing party, (b) is disclosed to the receiving party free of confidentiality obligations by a Third Party who has the right to make such disclosure without obligations of confidentiality,
(c) is or becomes part of the public domain or otherwise publicly known through no fault of the receiving party, or (d) the receiving party can reasonably establish is independently developed by persons on behalf of receiving party without
the use of the Confidential Information disclosed by the disclosing party. 
 1.5 “FDA” means the United States
Food and Drug Administration or any successor entity thereto. 
 1.6 “GAAP” means generally accepted accounting
principles in effect in the United States from time to time, as consistently applied by the applicable party with regard to their own products and/or standards of the industry. 

1.7 “Generic Equivalent” means ***. 
 1.8 “Generic Product” means ***. 
 1.9 “Grantback
Patents” means (a) ***, (b) all divisions, continuations, continuations-in-part, that in whole or in part claim priority to, or common priority with, the patent applications described in clause (a) above or the patent
applications that resulted in the patents described in clause (a) above, and (c) all patents that have issued or in the future issue from any of the foregoing patent applications, together with any reexamination certificates, reissues or
restorations by existing or future extension or restoration mechanisms, or additions thereto. 
 1.10 “License
Trigger” means, with respect to a Generic Equivalent to a Vanos Product, the earliest of the following dates: 
  

	 	(a)	December 15, 2013; 

  

	 	(b)	***; and 

  

	 	(c)	***. 

 1.11 “Net
Sales” means ***. 

  
 2 

 1.12 “Orange Book” means the publication, Approved Drug Products with
Therapeutic Equivalence Evaluations, in electronic or hard copy form, maintained by the FDA, including all supplements thereto. 

1.13 “Patents-in-Suit” means ***. 
 1.14 “Patent Rights” means (a) the patents and patent applications listed on Exhibit A to this Agreement, (b) all divisions, continuations, continuations-in-part that in whole
or in part claim priority to, or common priority with, the patent applications described in clause (a) above or the patent applications that resulted in the patents described in clause (a) above, (c) all patents that have issued or in
the future issue from any of the foregoing patent applications, and (d) any additional patents owned or controlled by Medicis covering a Generic Product or the manufacture or use of a Generic Product, together with any reexamination
certificates, reissues or restorations by existing or future extension or restoration mechanisms, or additions thereto. 

1.15 ***. 
 1.16 “Product” means any product for which the making, using, selling or importation is covered by one or more claims of the Patent Rights. 

1.17 “Profit” means ***. 
 1.18 “Territory” means the United States of America, its territories and possessions ***. 
 1.19 “Third Party” means any person or entity other than Medicis or Nycomed or their respective Affiliates. 
 1.20 “Transfer Price” means ***. Such ***, as of the Effective Date, are set forth on Exhibit E ***. 

1.21 “Valid Claim” means ***. 
 1.22 “Vanos Products” means the Vanos products listed on Exhibit B, as such products are marketed and sold by Medicis in the Territory. 

 

	 	2.	LICENSES; RELEASES. 

 2.1
License Grant for Generic Product. 
 2.1.1 Effective only upon the occurrence of the License Trigger for a Generic
Product, Medicis hereby grants to Nycomed a non-exclusive, non-transferable (except as permitted in Section 9.5) license (without the right to grant sublicenses except to have Generic Products made on behalf of Nycomed) under the Patent Rights
(a) to make or have made such Generic Product in the Territory or outside the Territory solely for sale in the Territory, (b) to use, offer for sale and sell such Generic Product inside the Territory, and (c) to import such Generic
Product into the Territory. 

  
 3 

 2.1.2 Until the occurrence of the applicable License Trigger, neither Nycomed nor its
Affiliates shall, and neither shall directly or indirectly encourage or assist any Third Party to, develop, make, use and/or commercialize any Generic Products or Generic Equivalents in the Territory ***. 

2.1.3 Except pursuant to the Distribution Agreement (defined in Section 3), nothing in this Agreement shall be construed as
creating an obligation, express or implied, on Medicis to supply any Product to Nycomed and Nycomed shall be solely responsible for manufacturing, or having manufactured, its supply of Generic Product. 

2.2 Grantback. Nycomed and its Affiliates hereby grant to Medicis a perpetual (subject to section 5.3), royalty-free, fully-paid
up, non-transferable (except as provided in Section 9.5), non-exclusive license (with the right to grant sublicenses through multiple tiers) under the Grantback Patents to make, have made, use, offer for sale, sell and import Vanos Products or
Generic Equivalents in the Territory. 
 2.3 Validity of Patent Rights. 

2.3.1 Nycomed, on behalf of itself and its Affiliates, hereby acknowledges and agrees that the claims of the Patents-in-Suit are valid
and enforceable in this and in any other or future cause of action, litigation or proceeding in the United States involving Generic Products or Generic Equivalents. The foregoing acknowledgement regarding validity and enforceability shall be binding
upon Nycomed and its Affiliates and admissible against Nycomed and its Affiliates in any dispute or litigation between the parties regarding the Patents-in-Suit, and neither Nycomed nor its Affiliates will challenge any such acknowledgement.

 2.3.2 Nycomed, on behalf of itself and its Affiliates, hereby also acknowledges and agrees that the making, using, offering
to sell, selling, and/or importation into the Territory of a Generic Product is covered by one or more claims of the Patents-in-Suit under 35 U.S.C. § 271. 
 2.3.3 Nycomed shall not assist any Third Party in an action to, invalidate, amend or render unenforceable any of the Patent Rights, and Nycomed shall not disclose any of its proprietary or confidential
information relating to the validity or enforceability of any of the Patent Rights, except to the extent required by court order or other applicable law. 
 2.3.4 Nycomed shall not receive any ownership rights in the Patent Rights under this Agreement, and Medicis shall retain the sole right, to prepare, prosecute, maintain and enforce the Patent Rights.
Medicis shall not receive any ownership rights in the Grantback Patents under this Agreement, and Nycomed shall retain the sole right, to prepare, prosecute, maintain and enforce the Grantback Patents. 

2.4 No Implied Licenses. Except as explicitly set forth in this Agreement, neither party grants to the other party under its
patents or other intellectual property any license, express or implied. Nycomed shall not use Medicis’ name or any Medicis trademarks (including without limitation Vanos®) in connection with the marketing, promotion or sale of any products
without the prior written consent of Medicis in each instance; provided, however, that Nycomed may use the Medicis tradename Vanos (but not any associated logo or artwork) for the sole purpose of identifying the Generic Product or Authorized Generic
as being comparable to the applicable Vanos Product. 

  
 4 

 2.5 Releases. In consideration of the mutual covenants herein and in the Joint
Dismissal Agreements attached hereto as Exhibit C and incorporated herein by reference, and without limiting any remedies a party may have against the other party for a breach of this Agreement, Nycomed hereby releases and agrees to release Medicis
and its predecessors, successors, assigns, agents, officers, directors, shareholders, employees and representatives, and Medicis hereby releases and agrees to release Nycomed and its predecessors, successors, assigns, agents, officers, directors,
shareholders, employees and representatives, in each case, from any and all claims, damages, liabilities, obligations, and causes of action arising out of the Litigations. Upon the Effective Date, Nycomed and Medicis shall cause to be completed,
executed and filed with the Court a stipulated dismissal with prejudice of the Litigations, in the form of the Joint Dismissal Agreements attached hereto as Exhibit C, and to seek entry of such order by the Court. 

2.6 ***. 

2.7 ***. 
  

	 	3.	AUTHORIZED GENERIC DISTRIBUTION AGREEMENT. 

 3.1 Distribution Agreement. If, as of the License Trigger, Nycomed has not ***, then effective as of the License Trigger, Medicis hereby appoints Nycomed as its non-exclusive distributor of
the Authorized Generic in the Territory and authorizes Nycomed to market and sell the Authorized Generic solely to ***, pursuant to a separate distribution and supply agreement (the “Distribution Agreement”) to be entered
into between Nycomed and Medicis. 
 3.2 Terms. If Nycomed has not ***, then upon written notice by Nycomed at any
time after the Effective Date the parties shall negotiate in good faith the terms of and enter into the Distribution Agreement, which will contain the following provisions: 

 

	 	•	 	 Unless earlier terminated by either party for cause or by Nycomed for convenience, the term of any such appointment of Nycomed as the non-exclusive
distributor of the Authorized Generic shall extend from the License Trigger and remain in effect until such time as Nycomed has ***, but in no event longer than *** after the License Trigger (such term, the “Supply Term”);

  

	 	•	 	 Medicis will supply (either itself or through its Third Party manufacturer) Nycomed *** in the Territory for the Authorized Generic in finished
form; on such forecasting, invoicing, shipment, delivery, inspection and payment terms as are agreed upon by the parties and set forth in the Distribution Agreement; 

 

	 	•	 	 Medicis will sell the Authorized Generic to Nycomed at the Transfer Price; 

 

	 	•	 	 Nycomed shall retain *** of all Net Sales resulting from Nycomed’s sales of the Authorized Generic and shall pay the remaining ***
of such Net Sales to Medicis, on a quarterly basis ***; 

  
 5 

	 	•	 	 ***; 

  

	 	•	 	 Nycomed shall have no minimum purchase obligations with respect to the Authorized Generic; 

 

	 	•	 	 Nycomed will have the right, at its expense and upon *** prior written notice, to audit Medicis’ books and records no more than once a year
to confirm the Transfer Price and the rates paid by any Third Party with a distribution right in the Territory for a Generic Equivalent to the Vanos Product that is manufactured by or on behalf of Medicis; 

 

	 	•	 	 ***; and 

  

	 	•	 	 such other terms as the parties may agree and as are commercially reasonable and usual and customary for agreements of such type.

 3.3 ***. 
  

	 	4.	FINANCIAL CONSIDERATIONS. 

4.1 Royalty. 
 4.1.1 Within *** following the end of each calendar quarter during the term of this Agreement after the License Trigger, Nycomed shall pay to Medicis a royalty equal to *** of all ***
for Generic Product sold by Nycomed (or its designee) during such calendar quarter ***. Medicis’s right to receive a share of the *** of Generic Product under this Section 4.1.1 shall expire ***. 

4.1.2 Within *** following the end of each calendar quarter during the term of this Agreement after the License Trigger, Nycomed
shall provide to Medicis a written report stating the number and description of all Generic Products sold during the relevant calendar quarter; the gross sales associated therewith; the calculation of *** thereon, and the royalties that will
be payable for such calendar quarter in accordance with Section 4.1.1. 
 4.2 Taxes. Nycomed shall be responsible
for, and may withhold from payments made to Medicis under this Agreement, any taxes required to be withheld by Nycomed under applicable law. Accordingly, if any such taxes are levied on such payments due hereunder (“Withholding
Taxes”), Nycomed shall (i) deduct the Withholding Taxes from the payment amount, (ii) pay all applicable Withholding Taxes to the proper taxing authority, and (iii) send evidence of the obligation together with proof of tax
payment to Medicis within *** following that tax payment. 
 4.3 Audit Rights. Not more than once per calendar
year during the portion of the term of this Agreement during which Nycomed shall pay Medicis royalties, on no less than thirty (30) business days notice from Medicis, Nycomed shall make all such records, books of account, information and data
concerning (a) its sales of Generic Products pursuant to this Agreement; and (b) its calculation of Net Sales, in each case available for inspection during normal business hours by an independent auditor selected by Medicis and reasonably
acceptable to Nycomed for the purpose of an audit to determine the accuracy of the reports delivered and 

  
 6 

 
amounts paid by Nycomed pursuant to Section 4.1. Medicis shall be solely responsible for its costs in making any such audit, unless Medicis identifies a discrepancy in favor of Nycomed in
the calculation of the royalty owing on *** in any calendar year from those properly payable for that calendar year of *** or greater, in which event Nycomed shall be solely responsible for the reasonable cost of such audit and pay
Medicis any underpayment. ***. 
  

	 	5.	TERM AND TERMINATION. 

5.1 Term. Subject to Section 5.2, this Agreement shall expire on the date when there are no Valid Claims in the Territory

 5.2 Termination for Cause. Either party may terminate this Agreement upon or after the material breach of any material
provision of this Agreement by the other party if the other party has not cured such breach within *** after receipt of express written notice thereof by the non-breaching party. 

5.3 Effect of Expiration or Termination. Expiration or termination of this Agreement shall not relieve the parties of any
obligation accruing prior to such expiration or termination, and the provisions of Sections 2.2, 2.3, 2.4, 2.5, 4.3, 5.3, 6, 8 and 9 shall survive the expiration or termination of this Agreement, provided that Sections 2.2 and 2.3 shall
not survive termination of this Agreement by Nycomed pursuant to Section 5.2. Section 7.3 shall survive the expiration of this Agreement. ***. 
  

	 	6.	CONFIDENTIALITY. 

 6.1
Confidentiality. For a period of *** following the expiration or earlier termination of this Agreement, except with respect to any Confidential Information constituting a trade secret in which case the receiving party’s obligation
continues in perpetuity, provided such receiving party has been informed as to the status of such Confidential Information as a trade secret, each party shall maintain in confidence all Confidential Information disclosed by the other party, and
shall not use, grant the use of or disclose to any Third Party the Confidential Information of the other party other than as expressly permitted hereby. Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure
of the other party’s Confidential Information. 
 6.2 Permitted Disclosures. Either party may disclose Confidential
Information of the disclosing party (a) on a need-to-know basis, to such party’s directors, officers and employees to the extent such disclosure is reasonably necessary in connection with such party’s activities as expressly
authorized by this Agreement, and (b) to those agents and consultants, and contract manufacturers who need to know such information to accomplish the purposes of this Agreement (collectively, “Permitted Recipients”); provided
such Permitted Recipients are bound to maintain such Confidential Information in confidence at least to the same extent as set forth in Section 6. 
 6.3 Litigation and Governmental Disclosure. Each party may disclose Confidential Information of the other party to the extent such disclosure is reasonably necessary for prosecuting or defending
litigation, complying with a court order or applicable law, governmental regulations or investigation, provided that if a party is required by law or regulation 

  
 7 

 
to make any such disclosure of the other party’s Confidential Information it will give reasonable advance notice to the other party of such disclosure requirement and will use good faith
efforts to assist such other party to secure a protective order or confidential treatment of such Confidential Information required to be disclosed. 
 6.4 Limitation of Disclosure. The parties agree that, except as otherwise may be required by applicable laws, regulations, rules or orders, including without limitation the rules and regulations
promulgated by the United States Securities and Exchange Commission, the Department of Justice and the Federal Trade Commission, or any regulations of any national securities exchange, and except as may be authorized in Section 6.6, no
information concerning this Agreement and the transactions contemplated herein shall be made public by either party without the prior written consent of the other. 
 6.5 FTC/DOJ Filings. Within ten (10) business days following the Effective Date, the parties shall comply with the requirements of Title XI, Subtitle B of the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003, Pub. L. No. 108-173 (the “Act”), by filing or causing to be filed all necessary documents with the U.S. Federal Trade Commission (“FTC”) and the Antitrust Division of the U.S.
Department of Justice (“DOJ”). The parties shall use all commercially reasonable efforts to coordinate the foregoing filings and any responses thereto, to make such filings promptly and to respond promptly to any requests for additional
information made by either of the agencies, to coordinate any necessary or desirable joint presentations, or to overcome any objections raised by either of the agencies. Each party reserves the right to communicate with the agencies regarding such
filings as it believes appropriate. Each party shall keep the other informed of such communications (unless otherwise directed by either of the agencies) and shall not disclose any Confidential Information of the other party without that
party’s consent, which shall not be unreasonably withheld. 
 6.6 Publicity. Except for the press release attached
hereto as Exhibit D, neither party shall make any publicity releases, interviews or other non-confidential dissemination of information concerning this Agreement or its terms, or either party’s performance hereunder, to communication media,
financial analysts or others without the prior written approval of the other party, which approval shall not be unreasonably withheld, delayed or conditioned. Notwithstanding anything to the contrary in this Agreement, the parties understand and
agree that either party, may, if so required, disclose some or all of the information included in this Agreement or other Confidential Information of the other party (a) in order to comply with its obligations under the law, including the
United States Securities Act of 1933 and the United States Securities Exchange Act of 1934; (b) in order to comply with the listing standards or agreements of any national or international securities exchange or The NASDAQ Stock Market or New
York Stock Exchange or other similar laws of a governmental authority; (c) to respond to an inquiry of a governmental authority or regulatory authority as required by law; or (d) in a judicial, administrative or arbitration proceeding. In
any such event the party making such disclosure shall (i) provide the other party with as much advance notice as reasonably practicable of the required disclosure, (ii) cooperate with the other party in any attempt to prevent or limit the
disclosure, and (iii) limit any disclosure to the specific purpose at issue. In connection with any filing of a copy of this Agreement with the Securities and Exchange Commission, the filing party shall endeavor to obtain confidential treatment
of economic and trade secret information, and shall keep the other party informed as the planned filing (including, but not limited to providing the other party with the proposed filing reasonably in advance of making the planned filing) and
consider the requests of the other party regarding such confidential treatment. 

  
 8 

	 	7.	REPRESENTATIONS, WARRANTIES AND COVENANTS. 

 7.1 Representations. Each party hereby represents and warrants to the other party that (a) the person executing this Agreement is authorized to execute this Agreement; (b) this Agreement
is legal and valid and the obligations binding upon such party are enforceable by their terms; (c) the execution, delivery and performance of this License and Settlement Agreement has been duly authorized by all necessary corporate or other
organizational actions of the party and its Affiliates; and (d) the execution, delivery and performance of this Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which such party may be bound, nor
violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

7.2 Compliance with Law. Nycomed shall comply with all applicable laws and regulations with respect to obtaining regulatory
approval for the sale of Generic Products and its manufacture, sale and commercialization of Generic Products. Medicis shall comply with all applicable laws and regulations with respect to the manufacture of the Authorized Generic and sale thereof
to Nycomed. 
 7.3 ***. 
 7.4 ***. 
 7.5 Disclaimer of Warranties. Except for those warranties
expressly set forth in this Agreement, neither party makes any warranty, written, oral, express or implied, with respect to this Agreement. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT HEREBY ARE DISCLAIMED BY BOTH PARTIES. 
 7.6
Limitation of Liability. WITH THE EXCEPTION OF DAMAGES RESULTING FROM A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT OR ITS OBLIGATIONS UNDER SECTION 8, OR A BREACH BY NYCOMED OF SECTIONS 2.1.2 OR 2.3,
UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE FOR LOSS OF USE OR PROFITS OR OTHER COLLATERAL, SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR INDIRECT DAMAGES IN CONNECTION WITH THIS AGREEMENT, WHETHER SUCH CLAIMS ARE FOUNDED IN TORT OR
CONTRACT OR OTHERWISE. 
 7.7 Equitable Relief. Nycomed acknowledges and agrees that its obligations and undertakings
under this Agreement are reasonable and necessary to protect the legitimate interests of Medicis, that Medicis would not have entered into this Agreement in the absence of such provisions, and that Nycomed’s threatened breach or failure to
comply with Sections 2.1.2 or 2.3 of this Agreement shall cause Medicis significant and irreparable harm, the amount of which shall be extremely difficult to estimate and ascertain, and for which money damages shall not be adequate. Nycomed and
Medicis further acknowledge and agree that each shall have the right to 

  
 9 

 
apply to any court of competent jurisdiction for an injunction order restraining any breach or threatened breach of this Agreement and specifically enforcing the terms and provisions of this
Agreement, without the necessity of posting any bond or security, in addition to seeking any other remedy available in law or equity. 
  

	 	8.	INDEMNIFICATION. 

 8.1
***. 
 8.2 ***. 
 8.3 Obligations. A party which intends to claim indemnification under this Section 8 (the “Indemnified Party”) shall promptly notify the other party (the “Indemnifying
Party”) in writing of any claim, demand, action, or other proceeding in respect of which the Indemnified Party intends to claim such indemnification; provided, however, that failure to provide such notice within a reasonable period of time
shall not relieve the Indemnifying Party of any of its obligations hereunder except to the extent the Indemnifying Party is prejudiced by such failure. The Indemnified Party shall permit the Indemnifying Party, at its discretion, to settle any such
action, claim or other matter. Notwithstanding the foregoing, the Indemnifying Party shall not enter into any settlement that would adversely affect the Indemnified Party’s rights hereunder, or impose any obligations on the Indemnified Party in
addition to those set forth herein, in order for it to exercise such rights, without the Indemnified Party’s prior written consent, which shall not be unreasonably withheld or delayed. No such action, claim or other matter shall be settled
without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld or delayed. The Indemnified Party shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigation and
defense of any claim, demand, action, or other proceeding covered by the indemnification obligations of this Section 8. The Indemnified Party shall have the right, but not the obligation, to be represented in such defense by counsel of its own
selection and at its own expense. 
  

	 	9.	GENERAL PROVISIONS. 

 9.1
Notices. All notices hereunder shall be delivered by facsimile (confirmed by overnight delivery), or by overnight delivery with a reputable overnight delivery service, to the following address of the respective parties: 

 

			
	If to Medicis:	  	Medicis Pharmaceutical Corporation
		  	7720 North Dobson Road
		  	Scottsdale, Arizona 85256
		  	Attn: Chief Executive Officer
		  	Facsimile: 480-291-5175
		
	with a copy to:	  	Medicis Pharmaceutical Corporation
		  	7720 North Dobson Road
		  	Scottsdale, Arizona 85256
		  	Attn: General Counsel
		  	Facsimile: 480-291-8508

  
 10 

			
	If to Nycomed:	  	Nycomed US Inc.
		  	60 Baylis Road
		  	Melville, NY 11747
		  	Attention: Chief Executive Officer
		  	Facsimile: 631-454-6389
		
	With a copy to:	  	Nycomed US Inc.
		  	60 Baylis Road
		  	Melville, NY 11747-0103, United States
		  	Attention: General Counsel
		  	Facsimile: 631-420-1572

 Notices shall be effective on the day of receipt. A party may change its address listed above by notice
to the other party given in accordance with this Section 9.1. 
 9.2 Entire Agreement. The parties hereto
acknowledge that this Agreement sets forth the entire agreement and understanding of the parties and supersedes all prior written or oral agreements or understandings with respect to the subject matter hereof. No modification of any of the terms of
this Agreement, or any amendments thereto, shall be deemed to be valid unless in writing and signed by an authorized agent or representative of both parties hereto. No course of dealing or usage of trade shall be used to modify the terms and
conditions herein. This Agreement shall be binding on each of Nycomed and Medicis and their respective permitted successors and assigns. 
 9.3 Waiver. None of the provisions of this Agreement (including the Exhibits hereto) shall be considered waived by any party hereto unless such waiver is agreed to, in writing, by authorized agents
of such party. The failure of a party to insist upon strict conformance to any of the terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any party hereto.

 9.4 Obligations to Third Parties. Each party warrants and represents that this Agreement does not conflict with any
contractual obligations, expressed or implied, undertaken with any Third Party. 
 9.5 Assignment. Neither party shall
assign this Agreement or any part hereof or any interest herein (whether by operation of law or otherwise) to any Third Party (or use any subcontractor) without the written approval of the other party; provided, however, that either party may assign
this Agreement without such consent (i) to any Affiliate; and (ii) in the case of a merger, consolidation, change in control or sale of all or substantially all of the assets of the party relating to this Agreement and the resulting entity
assumes all of the obligations under this Agreement. No assignment shall be valid unless the permitted assignee(s) assumes all obligations of its assignor under this Agreement. No assignment shall relieve any party of responsibility for the
performance of its obligations hereunder. Any purported assignment in violation of this Section 9.5 shall be void. 

  
 11 

 9.6 Independent Contractor. Nycomed and Medicis are acting under this Agreement as
independent contractors and neither shall be considered an agent of, or joint venturer with, the other. Unless otherwise provided herein to the contrary, each party shall furnish all expertise, labor, supervision, machining and equipment necessary
for the performance of its obligations hereunder and shall obtain and maintain all building and other permits and licenses required by public authorities. 
 9.7 Governing Law. In any action brought regarding the validity, construction and enforcement of this Agreement, it shall be governed in all respects by the laws of the State of Delaware, without
regard to the principles of conflicts of laws. 
 9.8 Severability. If any term or provision of this Agreement shall for
any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or
provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never been contained herein. 
 9.9 Headings, Interpretation. The headings used in this Agreement are for convenience only and are not part of this Agreement. 

9.10 Counterparts. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. 
 [Remainder of this page intentionally blank]

  
 12 

 IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their
duly-authorized representatives effective as of the Effective Date. 
  

									
	NYCOMED US INC.	 	 	 	MEDICIS PHARMACEUTICAL CORPORATION
					
	By:	 	 /s/ Dave Klaum
	 		 	By:	 	 /s/ Richard D. Peterson

					
	Name:	 	 Dave Klaum
	 		 	Name:	 	 Richard D. Peterson

					
	Title:	 	 8/4/11
	 		 	Title:	 	 EVP, CFO & Treasurer

  
 13 

 EXHIBIT A 
 Patent Rights 
  

			
	 Patents
	  	 Pending Applications (all U.S.)

	***	  	***

 *** 

  
 A-1

 EXHIBIT B 
 Vanos Products 
  

			
	 PRODUCT
	  	 NDC

	Vanos (fluocinonide cream 0.1%) 30g	  	99207-0525-30
	Vanos (fluocinonide cream 0.1%) 60g	  	99207-0525-60
	  Vanos (fluocinonide cream 0.1%) 120g	  	99207-0525-10

  
 B-1

 EXHIBIT C 
 Joint Dismissal Agreements 
 IN THE UNITED STATES DISTRICT COURT

 FOR THE SOUTHERN DISTRICT OF NEW YORK 

 

					
	MEDICIS PHARMACEUTICAL	  	)	  	
	CORPORATION,	  	)	  	
		  	)	  	
	 Plaintiff,
	  	)	  	
		  	)	  	
	 v.
	  	)	  	C.A. No. 10-4140 (DLC)
		  	)	  	
	NYCOMED US INC. AND NYCOMED	  	)	  	
	GMBH,	  	)	  	
		  	)	  	
	 Defendants.
	  	)	  	
		  	)	  	

 STIPULATION AND ORDER OF DISMISSAL 

WHEREAS Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) brought this action asserting infringement of United States
Patent Nos. 6,765,001; 7,220,424; and 7,217,422 (the “Medicis Patents”); 
 WHEREAS Nycomed US Inc. submitted to the
U.S. Food and Drug Administration Abbreviated New Drug Application (“ANDA”) No. 200735 (the “Nycomed ANDA”) seeking approval to market and sell a generic fluocinonide cream USP, 0.1%, (the “Nycomed Product”);

 WHEREAS Nycomed US Inc.(“Nycomed”) and Medicis are parties to litigation in this Court relating to the Nycomed ANDA
and the Medicis Patents (“the Litigations”); 
 WHEREAS Nycomed GmbH was named as a defendant, but never served with
the Complaint in this action and Medicis intends by this Stipulation and Order of Dismissal to dismiss all claims in the Litigations against Nycomed GmbH with prejudice; 

  
 C-1

 WHEREAS Medicis and Nycomed have entered into a License and Settlement Agreement pursuant to
which they have resolved the Litigations; 
 WHEREAS the Court has made no factual or legal findings with regard to the Medicis
Patents or the Nycomed Product; 
 WHEREAS final settlement of the Litigations serves the public interest by saving judicial
resources and avoiding the risks and uncertainties to Medicis and Nycomed associated with litigation; 
 WHEREAS final
settlement of the Litigations will permit Medicis and Nycomed to save litigation costs, as well as adhere to the judicially recognized mandate that encourages the settlement of litigation whenever possible; 

NOW, THEREFORE, Medicis and Nycomed stipulate that: 
 1. Except as reserved and provided for in the License and Settlement Agreement, Nycomed, on behalf of itself and its subsidiaries and affiliates, acknowledges and agrees that the Nycomed Product that is
the subject of the Nycomed ANDA would, in the absence of the license granted by Medicis in the License and Settlement Agreement, infringe the Medicis Patents. 
 2. Except as reserved and provided for in the License and Settlement Agreements, Nycomed, on behalf of itself and its subsidiaries and affiliates, acknowledges and agrees that the Medicis Patents are
valid and enforceable with respect to the Nycomed Product. 
 3. All claims and counterclaims in this action are dismissed with
prejudice. 
 4. Except as set forth in the License and Settlement Agreement, each party shall bear its own costs, expenses and
attorneys’ fees in connection with this action. 
 5. The parties waive any right of appeal from this Stipulation and
Order. 

  
 C-2

 6. This Court shall retain jurisdiction of this action and over Medicis and Nycomed for
purposes of enforcement of the terms and obligations of this Stipulation and Order of Dismissal and the parties’ License and Settlement Agreement. 

  
 C-3

 IN THE UNITED STATES DISTRICT COURT 

FOR THE SOUTHERN DISTRICT OF NEW YORK 
  

					
	MEDICIS PHARMACEUTICAL	  	)	  	
	CORPORATION,	  	)	  	
		  	)	  	
	 Plaintiff,
	  	)	  	
		  	)	  	
	 v.
	  	)	  	C.A. No. 11-4551 (DLC)
		  	)	  	
	NYCOMED US INC.,	  	)	  	
		  	)	  	
		  	)	  	
	 Defendant.
	  	)	  	
		  	)	  	

 STIPULATION AND ORDER OF DISMISSAL 

WHEREAS Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) brought this action asserting infringement of United States
Patent No. 7,794,738 (the “Medicis Patent”) in the United States District Court for the District of Delaware (the “Delaware Court”); 
 WHEREAS Nycomed US Inc. submitted to the U.S. Food and Drug Administration Abbreviated New Drug Application (“ANDA”) No. 200735 (the “Nycomed ANDA”) seeking approval to market and
sell a generic fluocinonide cream USP, 0.1%, (the “Nycomed Product”); 
 WHEREAS the Delaware Court transferred this
action to this Court on June 16, 2011; 
 WHEREAS Nycomed US Inc.(“Nycomed”) and Medicis are parties to
litigation in this Court relating to the Nycomed ANDA and the Medicis Patent (“the Litigation”); 
 WHEREAS Medicis
and Nycomed have entered into a License and Settlement Agreement pursuant to which they have resolved the Litigation; 
 WHEREAS
the Court has made no factual or legal findings with regard to the Medicis Patents or the Nycomed Product; 

  
 C-4

 WHEREAS final settlement of the Litigation serves the public interest by saving judicial
resources and avoiding the risks and uncertainties to Medicis and Nycomed associated with litigation; 
 WHEREAS final
settlement of the Litigation will permit Medicis and Nycomed to save litigation costs, as well as adhere to the judicially recognized mandate that encourages the settlement of litigation whenever possible; 

NOW, THEREFORE, Medicis and Nycomed stipulate that: 
 1. Except as reserved and provided for in the License and Settlement Agreement, Nycomed, on behalf of itself and its subsidiaries and affiliates, acknowledges and agrees that the Nycomed Product that is
the subject of the Nycomed ANDA would, in the absence of the license granted by Medicis in the License and Settlement Agreement, infringe the Medicis Patent. 
 2. Except as reserved and provided for in the License and Settlement Agreement, Nycomed, on behalf of itself and its subsidiaries and affiliates, acknowledges and agrees that the Medicis Patent is valid
and enforceable with respect to the Nycomed Product. 
 3. All claims and counterclaims in this action are dismissed with
prejudice. 
 4. Except as set forth in the License and Settlement Agreement, each party shall bear its own costs, expenses and
attorneys’ fees in connection with this action. 
 5. The parties waive any right of appeal from this Stipulation and
Order. 
 6. This Court shall retain jurisdiction of this action and over Medicis and Nycomed for purposes of enforcement of the
terms and obligations of this Stipulation and Order of Dismissal and the parties’ License and Settlement Agreement. 

  
 C-5

 IN THE UNITED STATES DISTRICT COURT 

FOR THE SOUTHERN DISTRICT OF NEW YORK 
  

					
	MEDICIS PHARMACEUTICAL	  	)	  	
	CORPORATION,	  	)	  	
		  	)	  	
	 Plaintiff,
	  	)	  	
		  	)	  	
	 v.
	  	)	  	C.A. No. 11-2630 (DLC)
		  	)	  	
	NYCOMED US INC. AND NYCOMED	  	)	  	
	GMBH,	  	)	  	
		  	)	  	
	 Defendants.
	  	)	  	
		  	)	  	

 STIPULATION AND ORDER OF DISMISSAL 

WHEREAS Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) brought this action asserting infringement of United States
Patent Nos. 6,765,001; 7,220,424; and 7,217,422 (the “Medicis Patents”) in the United States District Court for the District of Delaware (the “Delaware Court”); 

WHEREAS Nycomed US Inc. submitted to the U.S. Food and Drug Administration Abbreviated New Drug Application (“ANDA”)
No. 200735 (the “Nycomed ANDA”) seeking approval to market and sell a generic fluocinonide cream USP, 0.1%, (the “Nycomed Product”); 
 WHEREAS the Delaware Court transferred this action to this Court on April 15, 2011; 
 WHEREAS Nycomed US Inc. (“Nycomed”) and Medicis are parties to litigation in this Court relating to the Nycomed ANDA and the Medicis Patents (“the Litigations”); 

WHEREAS Nycomed GmbH was named as a defendant, but never served with the Complaint in this action and Medicis intends by this Stipulation
and Order of Dismissal to dismiss all claims in the Litigations against Nycomed GmbH with prejudice; 

  
 C-6

 WHEREAS Medicis and Nycomed have entered into a License and Settlement Agreement pursuant to
which they have resolved the Litigations; 
 WHEREAS the Court has made no factual or legal findings with regard to the Medicis
Patents or the Nycomed Product; 
 WHEREAS final settlement of the Litigations serves the public interest by saving judicial
resources and avoiding the risks and uncertainties to Medicis and Nycomed associated with litigation; 
 WHEREAS final
settlement of the Litigations will permit Medicis and Nycomed to save litigation costs, as well as adhere to the judicially recognized mandate that encourages the settlement of litigation whenever possible; 

NOW, THEREFORE, Medicis and Nycomed stipulate that: 
 1. Except as reserved and provided for in the License and Settlement Agreement, Nycomed, on behalf of itself and its subsidiaries and affiliates, acknowledges and agrees that the Nycomed Product that is
the subject of the Nycomed ANDA would, in the absence of the license granted by Medicis in the License and Settlement Agreement, infringe the Medicis Patents. 
 2. Except as reserved and provided for in the License and Settlement Agreement, Nycomed, on behalf of itself and its subsidiaries and affiliates, acknowledges and agrees that the Medicis Patents are valid
and enforceable with respect to the Nycomed Product. 
 3. All claims and counterclaims in this action are dismissed with
prejudice. 
 4. Except as set forth in the License and Settlement Agreement, each party shall bear its own costs, expenses and
attorneys’ fees in connection with this action. 
 5. The parties waive any right of appeal from this Stipulation and
Order. 

  
 C-7

 6. This Court shall retain jurisdiction of this action and over Medicis and Nycomed for
purposes of enforcement of the terms and obligations of this Stipulation and Order of Dismissal and the parties’ License and Settlement Agreement. 

  
 C-8

 EXHIBIT D 
 Press Release 
 Nycomed US Inc. announced today the settlement of all patent litigation
with Medicis Pharmaceutical Corporation concerning fluocinonide cream, marketed by Medicis as Vanos®. Under the terms of the settlement, Nycomed US will be able to launch a generic version of Vanos® cream in December 2013, or earlier in
certain circumstances. 

  
 C-9

 EXHIBIT E 
 Vanos® *** 
  

			
	 PRODUCT
	  	 ***

	Vanos (fluocinonide cream 0.1%) 30g	  	***/EACH
	Vanos (fluocinonide cream 0.1%) 60g	  	***/EACH
	  Vanos (fluocinonide cream 0.1%) 120g	  	***/EACH

  
 C-10

 EXHIBIT F 
 ***. 

  
 C-11License and Settlement Agreement, dated as of September 6, 2011

 Exhibit 10.3 
 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 LICENSE AND SETTLEMENT AGREEMENT

 THIS LICENSE AND SETTLEMENT AGREEMENT (this “Agreement”) dated as of September 6, 2011 (the
“Effective Date”) is entered into between Medicis Pharmaceutical Corporation, a Delaware corporation with an address at 7720 North Dobson Road, Scottsdale, Arizona 85256, on behalf of itself and its Affiliates (collectively,
“Medicis”), and Aurobindo Pharma U.S.A., Inc., a Delaware corporation with an address at 102 Melrich Road, Cranbury, New Jersey 08512, on behalf of itself and its Affiliates (collectively “Aurobindo”). 

WHEREAS, Medicis is the owner of the Patent Rights (as defined below) and has filed complaints against Aurobindo in the action captioned
10-1050-LPS which is pending in the United States District Court, District of Delaware (the “Delaware Court”) and in the action captioned 3:10-cv-06318-MLC-LHG in the United States District Court, District of New Jersey (the
“New Jersey Court” and together with the Delaware Court, the “Courts”) (collectively, the “Litigation”); 
 WHEREAS, to avoid the expense of further litigation the Parties desire to settle the Litigation on the terms set forth herein; and 
 WHEREAS, the parties desire to settle the Litigation and Aurobindo desires to receive, and Medicis desires to grant to Aurobindo, a royalty-bearing license under the Patent Rights to make, use, sell,
offer for sale and import Current Generic Product and Future Generic Product (as each term is defined below), all on the terms and conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows: 
  

	1.	DEFINITIONS. 

 1.1
“55/80/105 Future Strengths Trigger Date” means, with respect to the 55/80/105 Future Generic Products only and for which Aurobindo has an approved ANDA, on a 55/80/105 Future Generic Product-by-55/80/105 Future Generic Product
basis, the earliest of: 
  

	 	(a)	February ***, 2019; 

  

	 	(b)	***; or 

  

	 	(c)	***. 

 ***. 

***. 
 1.2
“65/115 Future Strengths Trigger Date” means, with respect to the 65/115 Future Generic Products only and for which Aurobindo has an approved ANDA, on a 65/115 Future Generic Product-by-65/115 Future Generic Product basis, the
earliest of: 
  

	 	(a)	February ***, 2018; 

	 	(b)	***; or 

  

	 	(c)	***. 

 ***. 

***. 
 1.3
“Affiliate” means, with respect to any entity, any other entity that directly or indirectly controls, is controlled by, or is under common control with, such entity. An entity shall be regarded as in control of another entity if it
owns, or directly or indirectly controls, at least fifty percent (50%) of the voting stock or other ownership interest of the other entity, or if it directly or indirectly possesses the power to direct or cause the direction of the management
and policies of the other entity by any means whatsoever. 
 1.4 “Business Day” shall mean any day other than a
Saturday, a Sunday or a day on which the state or federal courts located in the State of Delaware are authorized or obligated by law or executive order to be closed. 
 1.5 “Confidential Information” means all non-public materials, information and data concerning the disclosing party and its operations that is disclosed by the disclosing party to the
receiving party pursuant to this Agreement, orally or in written, electronic or tangible form, or otherwise obtained by the receiving party through observation or examination of the disclosing party’s operations. Confidential Information
includes, but is not limited to, information about the disclosing party’s financial condition and projections; business, marketing or strategic plans; sales information; customer lists; price lists; databases; trade secrets; product prototypes
and designs; techniques, formulae, algorithms and other non-public process information. Notwithstanding the foregoing, Confidential Information of a party shall not include that portion of such materials, information and data that the recipient can
establish by written documentation: (a) is known to the recipient or any of the recipient’s Affiliates as evidenced by its written records before receipt thereof from the disclosing party, (b) is disclosed to the recipient or any of
the recipient’s Affiliates free of confidentiality obligations by a Third Party who has the right to make such disclosure without obligations of confidentiality, (c) is or becomes part of the public domain through no fault of the
recipient, or (d) the recipient can reasonably establish is independently developed by persons on behalf of recipient or any of its Affiliates without the use of the information disclosed by the disclosing party. 

1.6 “Current Generic Product” means *** in 45mg, 90mg or 135mg dosage strengths. 

1.7 “Current Solodyn Products” means the Solodyn® products listed on Exhibit A. 

1.8 “Current Strengths Trigger Date” means with respect to a Current Generic Product for which Aurobindo has an approved
ANDA, on a Current Generic Product-by-Current Generic Product basis, the earliest of: 
  

	 	(a)	November 26, 2011; 

  
 2 

	 	(b)	***; or 

  

	 	(c)	***. 

 ***. 

***. 
 1.9
“FDA” means the United States Food and Drug Administration or any successor entity thereto. 
 1.10
“Future Generic Product” means *** 
 1.11 “Future Solodyn Products” means the 55mg,
65mg, 80mg, 105mg and 115mg dosage strengths of the Solodyn-branded minocycline products that were approved by the FDA under the Medicis NDA. 
 1.12 “GAAP” means generally accepted accounting principles in effect in the United States from time to time, as consistently applied by Aurobindo. 

1.13 “Medicis NDA” means the New Drug Application #50-808 and any supplements or amendments thereto. 

1.14 “Net Sales” means ***. Subsections (a) through (d) shall be collectively referred to as
“Deductions”. 
 1.15 “Orange Book” means the current edition (in electronic or hard copy
form) of the FDA’s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, as may be amended from time to time, and any successor publication thereto. 

1.16 “Patent Rights” means (a) the patents, the patent applications giving rise thereto and patent applications
listed on Exhibit B to this Agreement, (b) all patents and patent applications issued or filed, respectively, in the United States that (i) claim or cover a product, composition, method, process or other patentable subject matter for a
Current Solodyn Product or a Future Solodyn Product, or the manufacture or use of such product and (ii) Medicis owns or controls as of the Effective Date or thereafter during the term of this Agreement; (c) all divisionals, continuations,
continuations-in-part and reissues that claim priority to, or common priority with, the patent applications described in clauses (a) and (b) above or the patent applications that resulted in the patents described in clauses (a) and
(b) above, and all patents granted thereon, and (d) all patents that have issued or in the future issue from any of the foregoing patent applications, together with any reexamination certificates, reissues or restorations by existing or
future extension or restoration mechanisms, or additions thereto. 
 1.17 “Pharmaceutical Equivalent” means a
product having the same active ingredient, the same dosage form, the same route of administration and the same strength or concentration as a given reference listed drug. 

  
 3 

 1.18 “Third Party” means any person or entity other than Medicis or
Aurobindo. 
 1.19 “United States” means the United States of America ***. 

1.20 “Valid Claim” means ***. 
  

	2.	RELEASE; PATENT RIGHTS. 

2.1 Prior to Trigger Dates. 
 2.1.1 Commencing on the Effective Date and continuing until the occurrence of a Current Strengths Trigger Date, Aurobindo shall not, and shall not directly or indirectly encourage or assist any Third
Party, on a voluntary basis, to develop, make, use, sell, offer for sale, or import into the United States such Current Generic Product, except as expressly permitted by the terms of this Agreement. ***. 

2.1.2 Commencing on the Effective Date and continuing until the occurrence of the 55/80/105 Future Strengths Trigger Date for a 55/80/105
Future Generic Product, on a 55/80/105 Future Generic Product-by-55/80/105 Future Generic Product basis, Aurobindo shall not, and shall not directly or indirectly encourage or assist any Third Party, on a voluntary basis, to develop, make, use,
sell, offer for sale, import or otherwise commercialize such 55/80/105 Future Generic Product, except as expressly permitted by the terms of this Agreement. ***. 
 2.1.3 Commencing on the Effective Date and continuing until the occurrence of the 65/115 Future Strengths Trigger Date for a 65/115 Future Generic Product, on a 65/115 Future Generic Product-by-65/115
Future Generic Product basis, Aurobindo shall not, and shall not directly or indirectly encourage or assist any Third Party, on a voluntary basis, to develop, make, use, sell, offer for sale, import or otherwise commercialize such 65/115 Future
Generic Product, except as expressly permitted by the terms of this Agreement. ***. 
 2.2 Validity of the Patent
Rights. Aurobindo hereby admits that the claims of the Patent Rights are valid and enforceable. Aurobindo hereby admits that the making, using, offering to sell, selling, and/or importation into the United States of a Current Generic Product or
a Future Generic Product, in each case, are covered by one or more claims of the Patent Rights under 35 U.S.C. § 271. The foregoing admissions, and any consent judgment incorporating same, shall be binding on Aurobindo and admissible against
Aurobindo in any dispute or litigation between the parties regarding the Patent Rights, and Aurobindo shall not challenge such admission. Aurobindo agrees that from the Effective Date forward, Aurobindo shall not assist any Third Party in an action
to invalidate or render unenforceable any Valid Claim, and Aurobindo shall not disclose any of its proprietary or confidential information relating to the validity or enforceability of any Valid Claim, except to the extent required by court order or
other applicable law. 
 2.3 Consent Judgment for Permanent Injunction & Stipulation and Order of Dismissal.
Upon the Effective Date, (1) Medicis and Aurobindo shall cause to be completed, executed and filed with the Delaware Court a Consent Judgment and Permanent Injunction in the forms attached hereto as Exhibit C, and Medicis, with Aurobindo’s
agreement, shall move for the entry of the Consent Judgment and Permanent Injunction by such Delaware Court, and (2) Medicis and Aurobindo shall cause to be completed, executed and filed with the NJ Court a Stipulation and Order of Dismissal in
the form attached hereto as Exhibit D. 

  
 4 

	3.	LICENSE. 

 3.1 License
Grants. 
 3.1.1 Subject to the terms and conditions of this Agreement, and effective on the Current Strengths Trigger Date,
Medicis hereby grants to Aurobindo a non-exclusive, non-transferable, non-sublicensable, royalty-bearing license under the Patents Rights to (a) make, have made, use, sell, offer for sale and import the applicable Current Generic Products in
the United States and (b) sell or offer for sale the applicable Current Generic Products in the United States to Aurobindo’s distributors including, without limitation, private label distributors and customers for ultimate resale by such
distributors, including own label distributors and customers in the United States. 
 3.1.2 Subject to the terms and conditions
of this Agreement, and effective on the applicable 55/80/105 Future Strengths Trigger Date for each applicable 55/80/105 Future Generic Product for which Aurobindo has an approved ANDA, Medicis hereby grants to Aurobindo a non-exclusive,
non-transferable, non-sublicensable, royalty-bearing license under the Patents Rights to (a) make, have made, use, sell, offer for sale and import in the United States the applicable 55/80/105 Future Generic Products for which Aurobindo has an
approved ANDA and (b) sell or offer for sale the applicable 55/80/105 Future Generic Products in the United States to Aurobindo’s distributors including, without limitation, private label distributors and customers for ultimate resale by
such distributors, including own label distributors and customers in the United States. 
 3.1.3 Subject to the terms and
conditions of this Agreement, and effective on the applicable 65/115 Future Strengths Trigger Date for each applicable 65/115 Future Generic Product for which Aurobindo has an approved ANDA, Medicis hereby grants to Aurobindo a non-exclusive,
non-transferable, non-sublicensable, royalty-bearing license under the Patents Rights to (a) make, have made, use, sell, offer for sale and import in the United States the applicable 65/115 Future Generic Products for which Aurobindo has an
approved ANDA and (b) sell or offer for sale the applicable 65/115 Future Generic Products in the United States to Aurobindo’s distributors including, without limitation, private label distributors and customers for ultimate resale by such
distributors, including own label distributors and customers in the United States. 
 3.2 No Licenses. Except as
otherwise provided herein, nothing in this Agreement shall be construed as: (a) an obligation to bring or prosecute actions or suits against Third Parties for infringement of any patent, whether within the Patent Rights or otherwise;
(b) conferring a right to use in advertising, publicity, promotion or otherwise any trademark or trade name of Medicis; or (c) granting by implication, estoppel or otherwise, any licenses or rights under the Patent Rights or any other
patents. 

  
 5 

	4.	ROYALTIES. 

 4.1
Payment. 
 4.1.1 Subject to the terms and conditions of this Agreement, within *** following the end of each
calendar quarter during the term of this Agreement, Aurobindo shall pay to Medicis in U.S. dollars a royalty of (a) *** of Net Sales of the Current Generic Product and (b) *** of Net Sales of the Future Generic Product during
such calendar quarter ***. All payments shall be made by wire transfer in US Dollars to such bank account as may be designated by Medicis in writing to Aurobindo. 
 4.1.2 Within *** following the end of each calendar quarter during the term of this Agreement, Aurobindo shall provide to Medicis a written estimate of the royalty amount that will be payable for
each product for such calendar quarter in accordance with Section 4.1.1. Within *** following the end of each calendar quarter during the term of this Agreement, Aurobindo shall provide to Medicis a written report stating the number and
description of all Current Generic Product and Future Generic Product sold during the relevant calendar quarter; the gross sales associated therewith; the calculation of Net Sales thereon, including without limitation the amount of any Deductions;
and the royalties that will be payable for such calendar quarter in accordance with Section 4.1.1. 
 4.1.3 Any late
payments shall bear interest at the lower of (a) *** per annum, or (b) the maximum rate allowed by law, commencing on the date payment is due. 
 4.2 Taxes. Aurobindo shall be responsible for and may withhold from payments made to Medicis under this Agreement any taxes required to be withheld by Aurobindo under applicable law. Accordingly,
if any such taxes are levied on such payments due hereunder (“Withholding Taxes”), Aurobindo shall (i) deduct the Withholding Taxes from the payment amount, (ii) pay all applicable Withholding Taxes to the proper taxing
authority, and (iii) send evidence of the obligation together with proof of tax payment to Medicis within *** following the applicable tax payment. 
 4.3 Audit Rights. Upon written notice from Medicis, Aurobindo shall make available for inspection during normal business hours by an independent auditor selected by Medicis and reasonably
acceptable to Aurobindo all records, books of account, information and data concerning the calculation of Net Sales pursuant to this Agreement for the purpose of an audit to determine the accuracy of the reports delivered and amounts paid by
Aurobindo pursuant to Section 4.1. Upon reasonable belief of discrepancy or dispute, Medicis’ external auditors shall be entitled to take copies or extracts from such records, books of account, information and data (but only to the extent
related to the contractual obligations set out in this Agreement) during any review or audit. Medicis shall be solely responsible for its costs in making any such audit, unless Medicis identifies a discrepancy in favor of Aurobindo in the
calculation of the Net Sales and royalties paid to Medicis under this Agreement in any calendar year from those properly payable for that calendar year of *** or greater, in which event Aurobindo shall be solely responsible for the reasonable
cost of such audit and pay Medicis any underpayment. 

  
 6 

	5.	TERM AND TERMINATION. 

5.1 Term. Subject to Sections 5.2 and 5.3, this Agreement shall expire on the expiration of the last to expire of the Patent
Rights; provided, however, that if there are no issued patents within the Patent Rights, but there are at such time pending patent applications within the Patent Rights, then subject to the terms and conditions of this Agreement, the term of this
Agreement shall continue for the pendency of such pending patent applications. 
 5.2 Termination for Cause. Either party
may terminate this Agreement upon or after the material breach of any material provision of this Agreement by the other party if the other party has not cured such breach within *** after receipt of express written notice thereof by the
non-breaching party. Upon termination of this Agreement, Aurobindo shall not make, have made, use, sell, offer for sale, import or distribute the applicable Current Generic Product or Future Generic Product. 

5.3 Termination for Challenge. Medicis shall have the right to immediately terminate this Agreement at any time after the
Effective Date in the event Aurobindo contests or challenges, or supports or assists any Third Party to contest or challenge, Medicis’ ownership of or rights in, or the validity, enforceability or scope of, any of the Patent Rights or seeks
(directly or through any Third Party) to raise a substantial new question of patentability in respect thereof. 
 5.4 Effect
of Expiration or Termination. Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, and the provisions of Sections 1, 2.2, 5.2, 5.4, 6, 7, 8 and 9 shall
survive the expiration or termination of this Agreement. No other provisions shall survive expiration or termination of this Agreement. 
  

	6.	CONFIDENTIALITY. 

 6.1
Confidentiality. Until the expiration or earlier termination of this Agreement, and for a period of *** following the expiration or earlier termination hereof or thereof, except with respect to any Confidential Information constituting
a trade secret in which case the receiving party’s obligation continues in perpetuity, provided such receiving party has been informed as to the status of such Confidential Information as a trade secret, each party shall maintain in confidence
all Confidential Information disclosed by the other party and the terms of this Agreement, and shall not use, grant the use of or disclose to any Third Party the Confidential Information of the other party other than as expressly permitted hereby.
Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other party’s Confidential Information or the terms of this Agreement. 

6.2 Permitted Disclosures. Either party may disclose Confidential Information of the disclosing party (a) on a need-to-know
basis, to such party’s or such party’s Affiliate’s directors, officers and employees to the extent such disclosure is reasonably necessary in connection with such party’s activities as expressly authorized by this Agreement, and
(b) to those agents and consultants, and contract manufacturers thereof who need to know such information to accomplish the purposes of this Agreement (collectively, “Permitted Recipients”); provided such Permitted Recipients
are bound to maintain such Confidential Information in confidence at least to the same extent as set forth in Section 6.1. 

  
 7 

 6.3 Litigation and Governmental Disclosure. Each party may disclose Confidential
Information of the other party to the extent such disclosure is reasonably necessary for prosecuting or defending litigation or complying with a court order or applicable law, governmental regulations or investigation, provided that if a party is
required by court order, law or regulation (except for disclosure requested or required by the I.R.S.) to make any such disclosure of the other party’s Confidential Information it will give reasonable advance notice to the other party of such
disclosure requirement and will use good faith efforts to assist such other party to secure a protective order or confidential treatment of such Confidential Information required to be disclosed. 

6.4 Return of Confidential Information. Upon expiration or termination of this Agreement for any reason, the Receiving Party, upon
receipt of a written request from the Disclosing Party, shall return to the Disclosing Party all copies of the Confidential Information received from the Disclosing Party hereunder, or, in its discretion, destroy all such copies and certify to such
destruction, provided, however, that the Receiving Party’s legal counsel may retain one copy of such Confidential Information in a secure location solely for purposes of determining the Receiving Party’s continuing obligations under this
Agreement. 
 6.5 Publicity. Neither party shall make any publicity releases, interviews or other dissemination of
information concerning this Agreement or its terms, or either party’s performance hereunder, to communication media, financial analysts or others without the prior written approval of the other party, which approval shall not be unreasonably
withheld, delayed or conditioned. Notwithstanding anything to the contrary in this Agreement, the parties understand and agree that either party, may, if so required, disclose some or all of the information included in this Agreement or other
Confidential Information of the other party (a) in order to comply with its obligations under the law, including the United States Securities Act of 1933 and the United States Securities Exchange Act of 1934 and The Drug Price Competition and
Patent Term Restoration Act of 1984, as amended by The Medicare Prescription Drug, Improvement and Modernization Act of 2003; (b) in order to comply with the listing standards or agreements of any national or international securities exchange
or The NASDAQ Stock Market or New York Stock Exchange or other similar laws of a governmental authority; (c) to respond to an inquiry of a governmental authority or regulatory authority as required by law; or (d) in a judicial,
administrative or arbitration proceeding. In any such event the party making such disclosure shall (i) provide the other party with as much advance notice as reasonably practicable of the required disclosure, (ii) cooperate with the other
party in any attempt to prevent or limit the disclosure, and (iii) limit any disclosure to the specific purpose at issue. In connection with any filing of a copy of this Agreement with the Securities and Exchange Commission, the filing party
shall endeavor to obtain confidential treatment of economic and trade secret information, and shall keep the other party informed as the planned filing (including, but not limited to providing the other party with the proposed filing reasonably in
advance of making the planned filing) and consider the requests of the other party regarding such confidential treatment. 

  
 8 

	7.	REPRESENTATIONS AND WARRANTIES. 

 7.1 Representations. Each party hereby represents and warrants as of the Effective Date to the other party that (a) the person executing this Agreement is authorized to execute this Agreement;
(b) this Agreement is legal and valid and the obligations binding upon such party are enforceable by their terms; and (c) the execution, delivery and performance of this Agreement does not conflict with any agreement, instrument or
understanding, oral or written, to which such party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

7.2 Disclaimer of Warranties. Except for those warranties set forth in Section 7.1, neither party makes any warranty,
written, oral, express or implied, with respect to this Agreement. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE HEREBY ARE DISCLAIMED BY BOTH
PARTIES. 
 7.3 Limitation of Liability. WITH THE EXCEPTION OF DAMAGES RESULTING FROM A PARTY’S BREACH OF ITS
CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT OR ITS OBLIGATIONS UNDER SECTION 8 (INDEMNIFICATION), OR A BREACH BY AUROBINDO OF SECTIONS 2.1 OR 2.2, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE FOR LOSS OF USE OR PROFITS OR OTHER
COLLATERAL, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, WHETHER SUCH CLAIMS ARE FOUNDED IN TORT OR CONTRACT. 
 7.4 Equitable Relief. Aurobindo acknowledges and agrees that the obligations and undertakings of Aurobindo pursuant to Sections 2.1 and 2.2 of this Agreement are reasonable and necessary to
protect the legitimate interests of Medicis, that Medicis would not have entered into this Agreement in the absence of such provisions, and that Aurobindo’s breach or threatened breach or failure to comply with Sections 2.1 and 2.2 shall
cause Medicis significant and irreparable harm, the amount of which shall be extremely difficult to estimate and ascertain, and for which money damages shall not be adequate. Aurobindo further acknowledges and agrees that Medicis shall have the
right to apply to any court of competent jurisdiction for an injunction order restraining any breach or threatened breach of Sections 2.1 and 2.2 of this Agreement and specifically enforcing the terms and provisions of such Sections of this
Agreement, without the necessity of posting any bond or security, in addition to seeking any other remedy available to Medicis in law or equity. Aurobindo agrees that it shall not challenge any of the foregoing acknowledgements and agreements
concerning injunctive relief in any proceeding brought by Medicis. 
  

	8.	INDEMNIFICATION. 

 8.1
***. 
 8.2 Obligations. Medicis shall promptly notify Aurobindo in writing of any claim, demand, action, or other
proceeding in respect of which Medicis intends to claim such 

  
 9 

 
indemnification; provided, however, that failure to provide such notice within a reasonable period of time shall not relieve Aurobindo of any of its obligations hereunder except to the extent
Aurobindo is prejudiced by such failure. Medicis shall permit Aurobindo, at its discretion, to settle any such action, claim or other matter. Notwithstanding the foregoing, Aurobindo shall not enter into any settlement that would adversely affect
Medicis’s rights hereunder, or impose any obligations on Medicis in addition to those set forth herein, in order for it to exercise such rights, without Medicis’s prior written consent, which shall not be unreasonably withheld or delayed.
No such action, claim or other matter shall be settled without the prior written consent of Aurobindo, which shall not be unreasonably withheld or delayed. Medicis shall reasonably cooperate with Aurobindo and its legal representatives in the
investigation and defense of any claim, demand, action, or other proceeding covered by the indemnification obligations of this Section 8. Medicis shall have the right, but not the obligation, to be represented in such defense by counsel of its
own selection and at its own expense. 
  

	9.	GENERAL PROVISIONS. 

 9.1
Notices. All notices hereunder shall be delivered by facsimile (confirmed by overnight delivery), or by overnight delivery with a reputable overnight delivery service, to the following address of the respective parties: 

 

			
	If to Medicis:	  	Medicis Pharmaceutical Corporation
		  	7720 North Dobson Road
		  	Scottsdale, Arizona 85256
		  	Attn: Chief Executive Officer
		  	Facsimile: 480-291-5175
		
	with a copy to:	  	Medicis Pharmaceutical Corporation
		  	7720 North Dobson Road
		  	Scottsdale, Arizona 85256
		  	Attn: General Counsel
		  	Facsimile: 480-291-8655
		
	If to Aurobindo:	  	Aurobindo Pharma U.S.A., Inc.
		  	102 Melrich Road
		  	Cranbury, New Jersey 08512
		  	Attn: Chief Executive Officer
		  	Facsimile: (732) 355-0312
		
	With a copy to:	  	Aurobindo Pharma Ltd.
		  	Survey No. 313, Bachupally
		  	R. R. District, Hyderabad-500072
		  	Andhra Pradesh, India
		  	Attn: G. P. Prasad
		  	Facsimile: : +91 40 2304 4058

 Notices shall be effective on the day of receipt. A party may change its address listed above by notice to the other
party given in accordance with this Section 9.1. 

  
 10 

 9.2 Entire Agreement. The parties hereto acknowledge that this Agreement sets forth
the entire agreement and understanding of the parties and supersedes all prior written or oral agreements or understandings with respect to the subject matter hereof. No modification of any of the terms of this Agreement, or any amendments thereto,
shall be deemed to be valid unless in writing and signed by an authorized agent or representative of both parties hereto. No course of dealing or usage of trade shall be used to modify the terms and conditions herein. This Agreement shall be binding
on each of Aurobindo and Medicis and their respective permitted successors and assigns. 
 9.3 Waiver. None of the
provisions of this Agreement shall be considered waived by any party hereto unless such waiver is agreed to, in writing, by authorized agents of such party. The failure of a party to insist upon strict conformance to any of the terms and conditions
hereof, or failure or delay to exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any party hereto. 
 9.4 Obligations to Third Parties. Each party warrants and represents that this Agreement does not conflict with any contractual obligations, expressed or implied, undertaken with any Third Party.

 9.5 Assignment. Neither party shall assign this Agreement or any part hereof or any interest herein (whether by
operation of law or otherwise) to any Third Party (or use any subcontractor) without the written approval of the other party; provided, however, that either party may assign this Agreement without such consent (i) to any Affiliate; and
(ii) in the case of a merger, consolidation, change in control or sale of all or substantially all of the assets related to this Agreement, provided further that with respect to Aurobindo, any such Affiliate or Third Party agrees to be bound by
the terms and conditions of this Agreement including, without limitation, the provisions of Section 2.2. No assignment shall be valid unless the permitted assignee(s) assumes all obligations of its assignor under this Agreement. No assignment
shall relieve any party of responsibility for the performance of its obligations hereunder. Any purported assignment in violation of this Section 9.5 shall be void. 
 9.6 Governing Law. In any action brought regarding the validity, construction and enforcement of this Agreement, it shall be governed in all respects by the laws of the State of Delaware, without
regard to the principles of conflicts of laws. The federal and state courts in the State of Delaware shall have jurisdiction over the parties hereto in all matters arising hereunder and the parties hereto agree that the venue with respect to such
matters will be a state or federal court in the State of Delaware. 
 9.7 Severability. If any term or provision of this
Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if
such term or provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never been contained herein. 
 9.8 Headings, Interpretation. The headings used in this Agreement are for convenience only and are not part of this Agreement. 

  
 11 

 9.9 Attorneys’ Fees. The prevailing party shall be entitled to attorneys’
fees and its litigation or related expenses in any suit or proceeding with respect to the interpretation or enforcement of this Agreement. 
 9.10 Counterparts. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 [Remainder of this page intentionally blank] 

  
 12 

 IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by
their duly-authorized representatives effective as of the Effective Date. 
  

									
	AUROBINDO PHARMA U.S.A., INC.	 		 	MEDICIS PHARMACEUTICAL CORPORATION
					
	By:	 	 /s/ Scott J. White
	 		 	By:	 	 /s/ Jason D. Hanson

					
	Name:	 	 Scott J. White
	 		 	Name:	 	 Jason D. Hanson

					
	Title:	 	 Chief Executive Officer
	 		 	Title:	 	 Executive Vice President, Chief Operating Officer

				
	AUROBINDO PHARMA LTD.	 		 		 	
					
	By:	 	 /s/ G P Prasad
	 		 		 	
					
	Name:	 	 G P Prasad
	 		 		 	
					
	Title:	 	 VP Global Finance Operations
	 		 		 	

  
 13 

 EXHIBIT A 
 CURRENT SOLODYN PRODUCTS 
  

			
	 PRODUCT
	  	 NDC

	 Solodyn 45mg
	  	99207-0460-[All]
	 Solodyn 90mg
	  	99207-0461-[All]
	   Solodyn 135mg
	  	99207-0462-[All]

  
 14 

 EXHIBIT B 
 PATENT RIGHTS 
  

			
	 Issued Patents (all U.S.)
	 	Pending Applications (all U.S.)
		
	 ***
	 	***

  
 15 

 EXHIBIT C 
 Consent Judgment for Permanent Injunction in Delaware 
 IN THE UNITED
STATES DISTRICT COURT 
 FOR THE DISTRICT OF DELAWARE 

 

					
	MEDICIS PHARMACEUTICAL CORP,	  	)	  	
		  	)	  	
	 Plaintiff,
	  	)	  	
		  	)	  	
	v.	  	)	  	
		  	)	  	Civil Action No. 10-1050-LPS
	AUROBINDO PHARMA LTD. and	  	)	  	
	AUROBINDO PHARMA USA, INC.,	  	)	  	
		  	)	  	
	 Defendants.
	  	)	  	
		  	)	  	

 UNOPPOSED MOTION FOR ENTRY OF CONSENT JUDGMENT 

AND PERMANENT INJUNCTION AS TO 
 AUROBINDO PHARMA LTD. AND AUROBINDO PHARMA USA, INC. 
 Plaintiff
Medicis Pharmaceutical Corporation (“Medicis”) and Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. (collectively “Defendants”) having met, conferred, and agreed to resolve their dispute upon execution of a
separate License and Settlement Agreement (“Settlement Agreement”), Medicis respectfully moves for entry of the executed Consent Judgment and Permanent Injunction submitted herewith. Defendants do not oppose this motion. 

  
 16 

 
	
	MORRIS, NICHOLS, ARSHT & TUNNELL LLP
	
	  

	Jack B. Blumenfeld (#1014)
	Karen Jacobs Louden (#2881)
	1201 North Market Street
	Wilmington, DE 19899-1347
	(302) 658-9200
	 Jblumenfeld@mnat.com

klouden@mnat.com

	
	Attorneys for Plaintiff
	Medicis Pharmaceutical Corporation

 Dated: September 2, 2011 

  
 17 

 IN THE UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF DELAWARE 
  

					
	MEDICIS PHARMACEUTICAL CORP,	  	)	  	
		  	)	  	
	 Plaintiff,
	  	)	  	
		  	)	  	
	v.	  	)	  	
		  	)	  	Civil Action No. 10-1050-LPS
	AUROBINDO PHARMA LTD. and	  	)	  	
	AUROBINDO PHARMA USA, INC.,	  	)	  	
		  	)	  	
	 Defendants.
	  	)	  	
		  	)	  	

 CONSENT JUDGMENT AND PERMANENT INJUNCTION AS TO 

AUROBINDO PHARMA LTD. AND AUROBINDO PHARMA USA, INC. 

This matter is before the Court on the unopposed motion of Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) and
Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc., collectively (“Defendants”). 
 WHEREAS, this
Consent Judgment and Permanent Injunction as to Defendants concerns only the claims between Medicis and Defendants in this Civil Action No. 10-1050-LPS (referred to herein as the “Litigation”). 

WHEREAS, Medicis requests that this Consent Judgment and Permanent Injunction as to Defendants be entered in the above-captioned
case, and Defendants do not oppose Medicis’s request. 
 WHEREAS, Medicis owns United States Patent Nos. 5,908,838
(“the ‘838 patent”) and 7,790,705 (“the ‘705 patent”). 
 WHEREAS, Defendants submitted
Abbreviated New Drug Application No. 202-261 (“Aurobindo’s ANDA”) to the FDA under 21 U.S.C. § 355(j) seeking to obtain approval to commercially manufacture and sell generic minocycline HCl extended release tablets for
the treatment of acne. 

  
 1 

 WHEREAS, in the Litigation, Medicis alleged that Defendants infringed one or more of
claims 3, 4, 12, 13, 19, 21, 23, 25, and 27-34 of the ‘838 patent and one or more claims of the ‘705 patent under 35 U.S.C. § 271(e)(2) by virtue of Defendants’ submission of Aurobindo’s ANDA to the FDA. 

WHEREAS, in this Litigation, Medicis alleged that it would be irreparably harmed if Defendants are not enjoined from infringing or
actively inducing or contributing to infringement of one or more of claims 3, 4, 12, 13, 19, 21, 23, 25, and 27-34 of the ‘838 patent and one or more claims of the ‘705 patent. 

WHEREAS, in this Litigation, Medicis requested that this Court enter a permanent injunction enjoining Defendants from infringing
the ‘838 and ‘705 patents. 
 WHEREAS, Medicis and Defendants have reached an agreement to finally settle the
Litigation as set forth in this Consent Judgment and Permanent Injunction as to Defendants and a separate License and Settlement Agreement (“Settlement Agreement”) which is contemporaneously and separately being executed. 

WHEREAS, final settlement of the Litigation will help Medicis and Defendants avoid the substantial uncertainty and risks involved
with prolonged litigation. 
 WHEREAS, final settlement of this Litigation will permit Medicis and Defendants to save
litigation costs, as well as adhere to the judicially recognized mandate that encourages the settlement of litigation whenever possible. 

  
 2 

 WHEREAS, final settlement of the Litigation serves the public interest by saving
judicial resources and avoiding the risks to each of Medicis and Defendants associated with infringement. 
 WHEREAS,
Medicis and Defendants each consent to personal jurisdiction in Maryland for purposes of enforcing the Settlement Agreement. 
 IT IS HEREBY ORDERED, DECREED, and ADJUDGED as follows: 
 1. The Court has
jurisdiction over Medicis and Defendants and the subject matter of this Litigation. 
 2. Defendants acknowledge Medicis’s
ownership and standing to sue for infringement of United States Patent Nos. 5,908,838 (“the ‘838 patent”) and 7,790,705 (“the ‘705 patent”). 
 3. Defendants acknowledge that the ‘838 and ‘705 patents are valid and enforceable, as described more fully in the Settlement Agreement. 

4. Defendants and its affiliates are permanently enjoined as of the date hereof from infringing the ‘838 or ‘705 patents by the
manufacture, use, offer to sell, sale, importation, or distribution of any current products, or future products having the same strength and dosage form of the current Solodyn® products, that are the subject of Aurobindo’s ANDA that is not
pursuant to a license granted by Medicis, and from inducing others to infringe the ‘838 and ‘705 patents by inducing others to manufacture, use, offer to sell, sale, import, or distribute any current products, or future products having the
same strength and dosage form of the current Solodyn® products, that are the subject of Aurobindo’s ANDA that is not pursuant to a license granted by Medicis. 

  
 3 

 5. All claims and counterclaims in this Litigation are hereby dismissed without prejudice.

 6. The parties are hereby ordered to comply with the terms of the Settlement Agreement. 

7. Each party shall bear its own costs and attorneys’ fees. 

8. This Court shall retain jurisdiction over Defendants and Medicis for the purpose of enforcing the terms of this Consent Judgment and
Permanent Injunction and over any matters related to or arising from the interpretation or enforcement of the Settlement Agreement or any legal or equitable claim concerning the Settlement Agreement by any third party. 

IT IS SO ORDERED, DECREED AND ADJUDGED this      day of
            , 2011 by: 
  

	
	  

	The Honorable Leonard P. Stark
	United States District Judge

  
 4 

 Agreed to: 
  

					
	 MORRIS, NICHOLS, ARSHT & TUNNELL LLP

 
 Jack B. Blumenfeld (#1014)

Karen Jacobs Louden (#2881)
 MORRIS, NICHOLS,
ARSHT & TUNNELL LLP
 1201 North Market Street
 Wilmington, DE 19899-1347
 (302) 658-9200
 Jblumenfeld@mnat.com
 klouden@mnat.com

 
 Attorneys for Medicis Pharmaceutical Corporation
	 		 	 BAYARD, P.A.
  

Richard D. Kirk (#0922)
 Stephen B. Brauerman
(sb4952)
 222 Delaware Avenue, Suite 900

P.O. Box 25130
 Wilmington, DE
19899-5130
 (302) 655-5000

rkirk@bayardlaw.com

sbrauerman@bayardlaw.com
  
 Attorneys for Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.
  
 OF COUNSEL:
  
 Steven H.
Sklar
 LEYDIG, VOIT & MAYER, LTD.

Two Prudential Plaza, Suite 4900
 Chicago, IL
60601-6780
 Telephone: (312) 616-5600

Facsimile: (312) 616-5700

  
 5 

 EXHIBIT D 
 Stipulation and Order of Dismissal in New Jersey 
 IN THE UNITED STATES
DISTRICT COURT 
 FOR THE DISTRICT OF NEW JERSEY 

 

					
	MEDICIS PHARMACEUTICAL CORP.,	  	)	  	Civil Action No.10-6318(MLC/LGH)
		  	)	  	
	 Plaintiff,
	  	)	  	
		  	)	  	
	v.	  	)	  	
		  	)	  	
	AUROBINDO PHARMA LTD. and	  	)	  	
	AUROBINDO PHARMA USA, INC.,	  	)	  	
		  	)	  	
	 Defendants.
	  	)	  	
		  	)	  	

 STIPULATION AND ORDER OF DISMISSAL 

Plaintiff Medicis Pharmaceutical Corporation (“Medicis”) and Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.,
collectively (“Defendants”), by and through their undersigned counsel, hereby stipulate as follows pursuant to Rule 41(a) of the Federal Rules of Civil Procedure: 
 1. All claims and any counterclaims asserted in this suit by and between Medicis and Defendants are dismissed without prejudice; and 

2. Each party shall bear its own costs, expenses, and attorney fees. 

 SO STIPULATED: 
  

							
	 CONNELL FOLEY LLP
 Attorneys for Medicis Pharmaceutical Corporation
	 	 LEYDIG, VOIT & MAYER, LTD.
 Attorneys for Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.

  

													
		 	 BY:
	 	  
	 		 	BY:	 	  
	 	
		 		 	 Liza M. Walsh
 Rukhsanah L.
Lighari
 85 Livingston Avenue

Roseland, New Jersey 07068
 (973)
535-0500
	 		 		 	 Steven H. Sklar
 Two Prudential
Plaza, Suite 4900
 Chicago, IL 60601-6780
 (312) 616-5600
	 	
				
		 	 Dated: August     , 2011
	 	Dated: August     , 2011	 	

 SO ORDERED this     day of
            , 2011. 
  

	
	 
	Honorable Mary L. Cooper, U.S.D.J.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]